Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.4552W HIGH $19.45
Volume
58.29 K
Value Traded
4.01 M
Short % Float
7.5%
Days to Cover
5.6
+9.11%Week
+16.26%1 Month
+14.51%3 Month
+25.88%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.14 B
EPS (TTM)
-
P/E Ratio
-
Ent. Value
1.91 B
Total Shares
96.08 M
Float Shares
25.57 M
Insiders
73.39%
Institutions
33.10%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LMRI Catalyst Timeline
Dated clinical, regulatory and corporate events for Lumexa Imaging Holdings, Inc.
Past FDA Catalysts and PDUFA Decisions
How LMRI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Lumexa Imaging Holdings, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every LMRI program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BRODNAX BRETTDirector | Buy | 35,000 62,027 held | $7.25 | 05/19/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LMRI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 0.1 % | 7.33 M | 650.00 K |
LMRI Institutional Ownership Trends
LMRI Short Interest
Shares sold short, counted twice a month.
7.5%
Short % of Float
of tradable shares sold short
1.9M
Shares Sold Short
-5.2% vs prior count
5.6 High
Days to Cover
trading days of normal volume to buy every short share back
340.7K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LMRI ranks across every disease it competes in
Competitive Position is a premium feature
See how LMRI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLMRI News
-LMRI
Oct 28, 2026▲ +1.7%today
Lumexa Imaging Announces Third Quarter 2026 Earnings Conference Call Date
Lumexa Imaging (LMRI) will report third-quarter 2026 financial results after market close on November 10, 2026. The company will host a live webcast at 5:00 p.m. ET to discuss operational performance. This announcement follows the firm's 2025 data showing 4 million outpatient procedures across 190 centers.
Read more →-LMRI
Aug 25, 2026Lumexa Imaging Announces Participation in Upcoming Investor Conferences
Lumexa Imaging Holdings, Inc. announced its participation in several upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference and the JP Morgan High Yield Conference. CEO Caitlin Zulla and CFO Tony Martin will engage in fireside chats and one-on-one meetings with investors. The company aims to strengthen its investor relations and showcase its growth potential.
Read more →-LMRI
Aug 12, 2026Lumexa Imaging Announces Second Quarter 2026 Results
Lumexa Imaging reported strong second quarter results for 2026, with revenues increasing by 5.1% year-over-year to $264.2 million. The company announced the opening of four new imaging centers and a joint venture with Hospital for Special Surgery, marking significant growth in its operations. Despite a slight decrease in Adjusted EBITDA margin, the company remains optimistic about its full-year outlook.
Read more →-LMRI
Jul 29, 2026▼ -6.1%on this news
Lumexa Imaging Announces Second Quarter 2026 Earnings Conference Call Date
Lumexa Imaging has announced the date for its second quarter 2026 earnings conference call. The company will release its financial results on August 12, 2026, followed by a live webcast at 5:00 p.m. ET. This event highlights Lumexa's commitment to transparency and communication with stakeholders.
Read more →-LMRI
Jun 2, 2026Lumexa Imaging Announces Joint Venture with Hospital for Special Surgery (HSS) to Expand Advanced Outpatient Imaging in New York
Lumexa Imaging has announced a strategic joint venture with the Hospital for Special Surgery to enhance outpatient imaging services in New York. This partnership marks Lumexa's ninth joint venture and aims to expand access to advanced imaging across the NYC metro area. The collaboration is part of Lumexa's growth strategy to meet increasing demand for outpatient services.
Read more →-LMRI
May 12, 2026Lumexa Imaging Advances Growth Strategy by Adding Four New Imaging Centers
Lumexa Imaging has announced the addition of four new outpatient imaging centers in 2026, expanding its footprint in the Southeast and Mid-Atlantic regions. This growth includes a joint venture with UPMC in Pennsylvania and reflects the company's ongoing strategy to enhance access to imaging services through partnerships. The expansion aims to capitalize on favorable market trends and maintain a steady growth trajectory.
Read more →-LMRI
May 12, 2026Lumexa Imaging Announces First Quarter 2026 Results
Lumexa Imaging reported its first quarter 2026 results, highlighting a 3.1% increase in consolidated revenues to $252.5 million and a net income of $1.7 million, a significant turnaround from a loss in the previous year. The company reiterated its full-year guidance, expecting revenues between $1.045 to $1.097 billion. CEO Caitlin Zulla emphasized the company's strategic growth plans, including the addition of new imaging centers.
Read more →-LMRI
Apr 28, 2026Lumexa Imaging Announces First Quarter 2026 Earnings Conference Call Date
Lumexa Imaging has announced the release date for its first quarter 2026 financial results, set for May 12, 2026. The company will host a conference call at 5:00 p.m. ET to discuss these results. The audio webcast will be accessible on their Investor Relations website, with a replay available for one year.
Read more →-LMRI
Apr 20, 2026Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer
Lumexa Imaging has appointed Kyle Lynch as Chief Growth Officer to spearhead its growth strategy. Lynch will focus on expanding the company's platform through joint ventures and acquisitions while enhancing sales productivity. His experience in building business development organizations is expected to drive sustainable growth and improve operational performance. The appointment comes at a time when the outpatient imaging sector is experiencing significant demand.
Read more →-LMRI
Mar 26, 2026▼ -29.8%on this news
Lumexa Imaging Announces Fourth Quarter and Full Year 2025 Results, Reiterates Full Year 2026 Guidance
Lumexa Imaging reported strong financial results for Q4 and full year 2025, with revenues increasing by 7.9% to $267.7 million in the fourth quarter. The company also reiterated its guidance for 2026, expecting revenues between $1.045 to $1.097 billion. Despite a net loss of $28.7 million, the company achieved significant growth in Adjusted EBITDA and reduced leverage, positioning itself for future growth.
Read more →-LMRI
Mar 2, 2026▲ +12.2%on this news
Lumexa Imaging Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Results; Provides 2026 Financial Guidance and Earnings Conference Call Date
Lumexa Imaging has announced its preliminary unaudited financial results for the fourth quarter and full year 2025, indicating strong growth momentum with significant increases in outpatient procedures and advanced imaging services. The company expects at least a 14% growth in Adjusted EBITDA for 2026, bolstered by demand for innovative imaging technologies and new partnerships. The earnings conference call is scheduled for March 26, 2026, to discuss the outcomes and provide guidance for the upcoming year.
Read more →-LMRI
Feb 17, 2026▲ +6%on this newsshared move
Lumexa Imaging Announces Participation in Upcoming March 2026 Investor Conferences
Lumexa Imaging Holdings, Inc. has announced that CEO Caitlin Zulla and CFO Tony Martin will participate in upcoming investor conferences. This engagement aims to enhance the company's visibility and strengthen relationships with investors. Lumexa Imaging is a leading provider of outpatient imaging services, operating over 185 centers across 13 states.
Read more →-LMRI
Jan 28, 2026Lumexa Imaging’s Dr. Jennifer L. Kemp Elected to RSNA Board, Advancing National Leadership in Quality and Patient-Centered Care
Dr. Jennifer L. Kemp of Lumexa Imaging has been elected to the RSNA Board, enhancing leadership in radiology. Her role focuses on government relations and advancing patient-centered care. Lumexa Imaging's use of AI technology through Scanslated has significantly improved patient engagement, with high satisfaction reported among users.
Read more →-LMRI
Jan 8, 2026Lumexa Imaging Achieves Record De Novo Expansion in 2025
Lumexa Imaging has achieved a record by opening nine new outpatient imaging centers in 2025, expanding its footprint to over 185 centers across 13 states. The new locations, including centers in South Carolina and North Carolina, enhance access to affordable imaging services. The company aims to continue this growth strategy in 2026, focusing on high-growth metropolitan areas.
Read more →-LMRI
Jan 6, 2026Lumexa Imaging Announces Participation in Upcoming January 2026 Investor Conference
Lumexa Imaging Holdings, Inc. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. CEO Caitlin Zulla and CFO Tony Martin will present on January 12, 2026, in San Francisco. This event highlights Lumexa's significant role in the outpatient imaging sector, with a large operational footprint across the U.S.
Read more →-LMRI
Dec 12, 2025STOCKHOLDERS AGREEMENT by and among LUMEXA IMAGING HOLDINGS, INC. and THE ENTITIES NAMED IN THE PREAMBLE Dated as of
Lumexa Imaging Holdings, Inc. has entered into a Stockholders Agreement with several affiliated entities as it prepares for a potential initial public offering (IPO). This agreement, effective from December 12, 2025, outlines the governance structure and various operational provisions intended to enhance the management and oversight of the company. The parties aim to clarify their respective roles and responsibilities following the IPO's completion. The document suggests a strategic move towards enhancing stakeholder understanding and compliance as the company advances towards public trading.
Read more →-LMRI
Dec 10, 2025Lumexa Imaging Announces Pricing of Initial Public Offering
Lumexa Imaging Holdings, Inc. has priced its initial public offering at $18.50 per share, offering 25 million shares. The IPO is set to begin trading on the Nasdaq under the ticker 'LMRI' on December 11, 2025. The company has also granted underwriters a 30-day option to purchase additional shares. The offering is expected to close on December 12, 2025, subject to customary conditions.
Read more →-LMRI
Dec 2, 2025Lumexa Imaging Announces Launch of Initial Public Offering
Lumexa Imaging Holdings, Inc. has announced the launch of its initial public offering, offering 25 million shares priced between $17.00 and $20.00. The company has granted underwriters a 30-day option for an additional 3.75 million shares. The stock will be listed on the Nasdaq Global Market under the ticker 'LMRI'. Major financial firms are involved in the offering.
Read more →-LMRI
Aug 4, 2025Lumexa Imaging Names Radiologist Dr. Russell Stewart as Chief Medical Officer
Lumexa Imaging has appointed Dr. Russell Stewart as its new Chief Medical Officer. Dr. Stewart, a board-certified musculoskeletal radiologist, has a strong background in clinical radiology and healthcare innovation. He previously served as Chief Clinical Officer at Covera Health and has held leadership roles at Stanford University Medical Center. His role will focus on enhancing quality and patient safety while advancing technology-driven solutions.
Read more →About Lumexa Imaging Holdings, Inc.
Headquarters4200 SIX FORKS ROAD, RALEIGH, NC, 27609
BIOPHARMAWATCH ELITE PLUS
Trade the next LMRI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime